New brain scan study aims to uncover dementia clues in african americans

NCT ID NCT03618186

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses a special PET scan to look at tau protein buildup in the brains of African Americans who are either cognitively normal or have dementia. Researchers hope to learn how these brain changes differ across racial groups. The study involves 240 participants and uses a tracer called flutaucipir to highlight tau deposits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: flutaucipir (tau PET scan tracer)
What this could lead to: If successful, this study could help researchers better understand how tau protein buildup relates to cognitive impairment in African Americans, potentially guiding future diagnostic approaches.
What could go wrong: This is an observational imaging study, not a treatment trial. It is early-stage research focused on gathering data, so it will not directly lead to a new therapy. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COGNITIVE IMPAIRMENT

Contacts and locations

Locations

Mayo Clinic Minnesota

Rochester, Minnesota, 55905, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.